Join to access to all OVN content. Join for Free
The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins
MSLs in-house medical affairs HQ medical affairs Medical Science Liaison career advice

The Value of In-House Medical Affairs to the MSL E205 • May 14, 2024 • 29 mins


Share This Article


Summary

Erlene Seymour, Medical Director, US Medical Affairs Hematology at BeiGene discusses the value of In House or HQ Medical Affairs to the MSL.

Learn more about…

👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support
👉 What makes in house medical affairs so valuable to MSLs and to the organization
👉 Advice for MSLs in how they should view and interact with their inhouse counterparts
👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position
👉 What is it that helps MSLs stand out and separate themselves from the others

Click for Source
MSLs, in-house medical affairs, HQ medical affairs, Medical Science Liaison, career advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Four Employment Agreement Questions Every Pharma Executive Must Ask
Partner Avatar Michael Pietrack

The Four Employment Agreement Questions Every Pharma Executive Must Ask

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Explore OVN